HEADER TRANSFERASE/INHIBITOR 03-APR-20 6WFG TITLE CRYSTAL STRUCTURE OF HUMAN NAA50 IN COMPLEX WITH AN INHIBITOR TITLE 2 (COMPOUND 3) IDENTIFIED USING DNA ENCODED LIBRARY TECHNOLOGY COMPND MOL_ID: 1; COMPND 2 MOLECULE: N-ALPHA-ACETYLTRANSFERASE 50; COMPND 3 CHAIN: A, C, E; COMPND 4 SYNONYM: HNAA50P,N-ACETYLTRANSFERASE 13,N-ACETYLTRANSFERASE 5,HNAT5, COMPND 5 N-ACETYLTRANSFERASE SAN HOMOLOG,HSAN,N-EPSILON-ACETYLTRANSFERASE 50, COMPND 6 NATE CATALYTIC SUBUNIT, NAA50; COMPND 7 EC: 2.3.1.258,2.3.1.-; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: NAA50, MAK3, NAT13, NAT5; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008 KEYWDS N-ALPHA-ACETYLTRANSFERASE 50, INHIBITOR COMPLEX, DNA ENCODED LIBRARY, KEYWDS 2 COA, TRANSFERASE, TRANSFERASE-INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR S.E.GREASLEY,J.FENG,Y.-L.DENG,A.E.STEWART REVDAT 2 06-MAR-24 6WFG 1 REMARK REVDAT 1 01-JUL-20 6WFG 0 JRNL AUTH P.P.KUNG,P.BINGHAM,B.J.BURKE,Q.CHEN,X.CHENG,Y.L.DENG,D.DOU, JRNL AUTH 2 J.FENG,G.M.GALLEGO,M.R.GEHRING,S.K.GRANT,S.GREASLEY, JRNL AUTH 3 A.R.HARRIS,K.A.MAEGLEY,J.MEIER,X.MENG,J.L.MONTANO, JRNL AUTH 4 B.A.MORGAN,B.S.NAUGHTON,P.B.PALDE,T.A.PAUL,P.RICHARDSON, JRNL AUTH 5 S.SAKATA,A.SHAGINIAN,W.K.SONNENBURG,C.SUBRAMANYAM, JRNL AUTH 6 S.TIMOFEEVSKI,J.WAN,W.YAN,A.E.STEWART JRNL TITL CHARACTERIZATION OF SPECIFICN-ALPHA-ACETYLTRANSFERASE 50 JRNL TITL 2 (NAA50) INHIBITORS IDENTIFIED USING A DNA ENCODED LIBRARY. JRNL REF ACS MED.CHEM.LETT. V. 11 1175 2020 JRNL REFN ISSN 1948-5875 JRNL PMID 32550998 JRNL DOI 10.1021/ACSMEDCHEMLETT.0C00029 REMARK 2 REMARK 2 RESOLUTION. 2.16 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.16 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 64.79 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 88.5 REMARK 3 NUMBER OF REFLECTIONS : 29778 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.203 REMARK 3 R VALUE (WORKING SET) : 0.201 REMARK 3 FREE R VALUE : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.070 REMARK 3 FREE R VALUE TEST SET COUNT : 1511 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 15 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.16 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.24 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 72.10 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2377 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2360 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2259 REMARK 3 BIN R VALUE (WORKING SET) : 0.2350 REMARK 3 BIN FREE R VALUE : 0.2650 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.96 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 118 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3676 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 246 REMARK 3 SOLVENT ATOMS : 142 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 56.42 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 61.08 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -15.34450 REMARK 3 B22 (A**2) : 10.88710 REMARK 3 B33 (A**2) : 4.45740 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.18140 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.290 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.241 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.205 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.251 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.209 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.935 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.870 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4120 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 5697 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1433 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 102 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 579 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4120 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 503 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 4582 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.17 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.02 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 17.43 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6WFG COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-APR-20. REMARK 100 THE DEPOSITION ID IS D_1000248127. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-JUL-17 REMARK 200 TEMPERATURE (KELVIN) : 93 REMARK 200 PH : 5.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS3 S 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS 0.5.31 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 29839 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.160 REMARK 200 RESOLUTION RANGE LOW (A) : 64.790 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 88.5 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : 0.04400 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 14.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.16 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.28 REMARK 200 COMPLETENESS FOR SHELL (%) : 58.1 REMARK 200 DATA REDUNDANCY IN SHELL : 3.30 REMARK 200 R MERGE FOR SHELL (I) : 0.63900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: AUTOBUSTER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.72 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.72 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SOAK OF COMPOUND INTO COA BOUND REMARK 280 CRYSTALS. NAA50 APO PROTEIN (14.3 MG/ML) WAS INCUBATED WITH COA REMARK 280 IN A 1:3 MOLAR RATIO ON ICE FOR 60 MIN. CRYSTALLIZATION SOLUTION: REMARK 280 0.1 M NA ACETATE, PH5.0, 25% (W/V) PEG 3350, 10 MM REMARK 280 DITHIOTHREITOL (DTT), AND 0.1% DIOXANE, VAPOR DIFFUSION, SITTING REMARK 280 DROP, TEMPERATURE 294.15K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 51.47000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -1 REMARK 465 SER A 0 REMARK 465 MET A 1 REMARK 465 LYS A 2 REMARK 465 GLY A 3 REMARK 465 SER A 4 REMARK 465 LYS A 155 REMARK 465 VAL A 156 REMARK 465 PRO A 157 REMARK 465 SER A 158 REMARK 465 GLY A 159 REMARK 465 GLN A 160 REMARK 465 ASN A 161 REMARK 465 ALA A 162 REMARK 465 ASP A 163 REMARK 465 VAL A 164 REMARK 465 GLN A 165 REMARK 465 LYS A 166 REMARK 465 THR A 167 REMARK 465 ASP A 168 REMARK 465 ASN A 169 REMARK 465 GLY C -1 REMARK 465 SER C 0 REMARK 465 MET C 1 REMARK 465 LYS C 2 REMARK 465 LYS C 155 REMARK 465 VAL C 156 REMARK 465 PRO C 157 REMARK 465 SER C 158 REMARK 465 GLY C 159 REMARK 465 GLN C 160 REMARK 465 ASN C 161 REMARK 465 ALA C 162 REMARK 465 ASP C 163 REMARK 465 VAL C 164 REMARK 465 GLN C 165 REMARK 465 LYS C 166 REMARK 465 THR C 167 REMARK 465 ASP C 168 REMARK 465 ASN C 169 REMARK 465 GLY E -1 REMARK 465 SER E 0 REMARK 465 MET E 1 REMARK 465 LYS E 2 REMARK 465 GLY E 3 REMARK 465 LYS E 155 REMARK 465 VAL E 156 REMARK 465 PRO E 157 REMARK 465 SER E 158 REMARK 465 GLY E 159 REMARK 465 GLN E 160 REMARK 465 ASN E 161 REMARK 465 ALA E 162 REMARK 465 ASP E 163 REMARK 465 VAL E 164 REMARK 465 GLN E 165 REMARK 465 LYS E 166 REMARK 465 THR E 167 REMARK 465 ASP E 168 REMARK 465 ASN E 169 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 141 CG CD NE CZ NH1 NH2 REMARK 470 ARG C 141 CG CD NE CZ NH1 NH2 REMARK 470 ARG E 141 CG CD NE CZ NH1 NH2 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue COA A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue U3V A 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue COA C 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue U3V C 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue COA E 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue U3V E 202 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 6WF3 RELATED DB: PDB REMARK 900 RELATED ID: 6WF5 RELATED DB: PDB DBREF 6WFG A 1 169 UNP Q9GZZ1 NAA50_HUMAN 1 169 DBREF 6WFG C 1 169 UNP Q9GZZ1 NAA50_HUMAN 1 169 DBREF 6WFG E 1 169 UNP Q9GZZ1 NAA50_HUMAN 1 169 SEQADV 6WFG GLY A -1 UNP Q9GZZ1 EXPRESSION TAG SEQADV 6WFG SER A 0 UNP Q9GZZ1 EXPRESSION TAG SEQADV 6WFG GLY C -1 UNP Q9GZZ1 EXPRESSION TAG SEQADV 6WFG SER C 0 UNP Q9GZZ1 EXPRESSION TAG SEQADV 6WFG GLY E -1 UNP Q9GZZ1 EXPRESSION TAG SEQADV 6WFG SER E 0 UNP Q9GZZ1 EXPRESSION TAG SEQRES 1 A 171 GLY SER MET LYS GLY SER ARG ILE GLU LEU GLY ASP VAL SEQRES 2 A 171 THR PRO HIS ASN ILE LYS GLN LEU LYS ARG LEU ASN GLN SEQRES 3 A 171 VAL ILE PHE PRO VAL SER TYR ASN ASP LYS PHE TYR LYS SEQRES 4 A 171 ASP VAL LEU GLU VAL GLY GLU LEU ALA LYS LEU ALA TYR SEQRES 5 A 171 PHE ASN ASP ILE ALA VAL GLY ALA VAL CYS CYS ARG VAL SEQRES 6 A 171 ASP HIS SER GLN ASN GLN LYS ARG LEU TYR ILE MET THR SEQRES 7 A 171 LEU GLY CYS LEU ALA PRO TYR ARG ARG LEU GLY ILE GLY SEQRES 8 A 171 THR LYS MET LEU ASN HIS VAL LEU ASN ILE CYS GLU LYS SEQRES 9 A 171 ASP GLY THR PHE ASP ASN ILE TYR LEU HIS VAL GLN ILE SEQRES 10 A 171 SER ASN GLU SER ALA ILE ASP PHE TYR ARG LYS PHE GLY SEQRES 11 A 171 PHE GLU ILE ILE GLU THR LYS LYS ASN TYR TYR LYS ARG SEQRES 12 A 171 ILE GLU PRO ALA ASP ALA HIS VAL LEU GLN LYS ASN LEU SEQRES 13 A 171 LYS VAL PRO SER GLY GLN ASN ALA ASP VAL GLN LYS THR SEQRES 14 A 171 ASP ASN SEQRES 1 C 171 GLY SER MET LYS GLY SER ARG ILE GLU LEU GLY ASP VAL SEQRES 2 C 171 THR PRO HIS ASN ILE LYS GLN LEU LYS ARG LEU ASN GLN SEQRES 3 C 171 VAL ILE PHE PRO VAL SER TYR ASN ASP LYS PHE TYR LYS SEQRES 4 C 171 ASP VAL LEU GLU VAL GLY GLU LEU ALA LYS LEU ALA TYR SEQRES 5 C 171 PHE ASN ASP ILE ALA VAL GLY ALA VAL CYS CYS ARG VAL SEQRES 6 C 171 ASP HIS SER GLN ASN GLN LYS ARG LEU TYR ILE MET THR SEQRES 7 C 171 LEU GLY CYS LEU ALA PRO TYR ARG ARG LEU GLY ILE GLY SEQRES 8 C 171 THR LYS MET LEU ASN HIS VAL LEU ASN ILE CYS GLU LYS SEQRES 9 C 171 ASP GLY THR PHE ASP ASN ILE TYR LEU HIS VAL GLN ILE SEQRES 10 C 171 SER ASN GLU SER ALA ILE ASP PHE TYR ARG LYS PHE GLY SEQRES 11 C 171 PHE GLU ILE ILE GLU THR LYS LYS ASN TYR TYR LYS ARG SEQRES 12 C 171 ILE GLU PRO ALA ASP ALA HIS VAL LEU GLN LYS ASN LEU SEQRES 13 C 171 LYS VAL PRO SER GLY GLN ASN ALA ASP VAL GLN LYS THR SEQRES 14 C 171 ASP ASN SEQRES 1 E 171 GLY SER MET LYS GLY SER ARG ILE GLU LEU GLY ASP VAL SEQRES 2 E 171 THR PRO HIS ASN ILE LYS GLN LEU LYS ARG LEU ASN GLN SEQRES 3 E 171 VAL ILE PHE PRO VAL SER TYR ASN ASP LYS PHE TYR LYS SEQRES 4 E 171 ASP VAL LEU GLU VAL GLY GLU LEU ALA LYS LEU ALA TYR SEQRES 5 E 171 PHE ASN ASP ILE ALA VAL GLY ALA VAL CYS CYS ARG VAL SEQRES 6 E 171 ASP HIS SER GLN ASN GLN LYS ARG LEU TYR ILE MET THR SEQRES 7 E 171 LEU GLY CYS LEU ALA PRO TYR ARG ARG LEU GLY ILE GLY SEQRES 8 E 171 THR LYS MET LEU ASN HIS VAL LEU ASN ILE CYS GLU LYS SEQRES 9 E 171 ASP GLY THR PHE ASP ASN ILE TYR LEU HIS VAL GLN ILE SEQRES 10 E 171 SER ASN GLU SER ALA ILE ASP PHE TYR ARG LYS PHE GLY SEQRES 11 E 171 PHE GLU ILE ILE GLU THR LYS LYS ASN TYR TYR LYS ARG SEQRES 12 E 171 ILE GLU PRO ALA ASP ALA HIS VAL LEU GLN LYS ASN LEU SEQRES 13 E 171 LYS VAL PRO SER GLY GLN ASN ALA ASP VAL GLN LYS THR SEQRES 14 E 171 ASP ASN HET COA A 201 48 HET U3V A 202 72 HET COA C 201 48 HET U3V C 202 72 HET COA E 201 48 HET U3V E 202 72 HETNAM COA COENZYME A HETNAM U3V (2S)-N-[(2S)-3-[1-(3-TERT-BUTYL-1-METHYL-1H-PYRAZOLE-5- HETNAM 2 U3V CARBONYL)PIPERIDIN-4-YL]-1-(METHYLAMINO)-1-OXOPROPAN- HETNAM 3 U3V 2-YL]-6-OXOPIPERIDINE-2-CARBOXAMIDE FORMUL 4 COA 3(C21 H36 N7 O16 P3 S) FORMUL 5 U3V 3(C24 H38 N6 O4) FORMUL 10 HOH *142(H2 O) HELIX 1 AA1 ASN A 15 PHE A 27 1 13 HELIX 2 AA2 ASN A 32 VAL A 42 1 11 HELIX 3 AA3 ALA A 81 ARG A 84 5 4 HELIX 4 AA4 GLY A 87 GLY A 104 1 18 HELIX 5 AA5 ASN A 117 LYS A 126 1 10 HELIX 6 AA6 ASN C 15 PHE C 27 1 13 HELIX 7 AA7 ASN C 32 VAL C 42 1 11 HELIX 8 AA8 ALA C 81 ARG C 84 5 4 HELIX 9 AA9 GLY C 87 GLY C 104 1 18 HELIX 10 AB1 ASN C 117 PHE C 127 1 11 HELIX 11 AB2 ASN E 15 PHE E 27 1 13 HELIX 12 AB3 ASN E 32 LEU E 40 1 9 HELIX 13 AB4 GLU E 41 GLU E 44 5 4 HELIX 14 AB5 ALA E 81 ARG E 84 5 4 HELIX 15 AB6 GLY E 87 GLY E 104 1 18 HELIX 16 AB7 ASN E 117 PHE E 127 1 11 SHEET 1 AA1 7 ILE A 6 ASP A 10 0 SHEET 2 AA1 7 ALA A 46 PHE A 51 -1 O TYR A 50 N GLU A 7 SHEET 3 AA1 7 ILE A 54 SER A 66 -1 O GLY A 57 N ALA A 49 SHEET 4 AA1 7 GLN A 69 CYS A 79 -1 O ARG A 71 N ASP A 64 SHEET 5 AA1 7 ASN A 108 GLN A 114 1 O ASN A 108 N LEU A 72 SHEET 6 AA1 7 ALA A 147 ASN A 153 -1 O HIS A 148 N VAL A 113 SHEET 7 AA1 7 GLU A 130 LYS A 135 -1 N GLU A 133 O VAL A 149 SHEET 1 AA2 7 ILE C 6 ASP C 10 0 SHEET 2 AA2 7 ALA C 46 PHE C 51 -1 O LEU C 48 N GLY C 9 SHEET 3 AA2 7 ILE C 54 SER C 66 -1 O GLY C 57 N ALA C 49 SHEET 4 AA2 7 GLN C 69 CYS C 79 -1 O ARG C 71 N ASP C 64 SHEET 5 AA2 7 ASN C 108 GLN C 114 1 O ASN C 108 N LEU C 72 SHEET 6 AA2 7 ALA C 147 ASN C 153 -1 O HIS C 148 N VAL C 113 SHEET 7 AA2 7 GLU C 130 LYS C 135 -1 N GLU C 133 O VAL C 149 SHEET 1 AA3 7 ILE E 6 ASP E 10 0 SHEET 2 AA3 7 ALA E 46 PHE E 51 -1 O LEU E 48 N GLY E 9 SHEET 3 AA3 7 ILE E 54 SER E 66 -1 O ILE E 54 N PHE E 51 SHEET 4 AA3 7 GLN E 69 CYS E 79 -1 O TYR E 73 N ARG E 62 SHEET 5 AA3 7 ASN E 108 GLN E 114 1 O TYR E 110 N LEU E 72 SHEET 6 AA3 7 ALA E 147 ASN E 153 -1 O HIS E 148 N VAL E 113 SHEET 7 AA3 7 GLU E 130 LYS E 135 -1 N GLU E 133 O VAL E 149 CISPEP 1 GLU A 143 PRO A 144 0 -0.24 CISPEP 2 GLU C 143 PRO C 144 0 -5.80 CISPEP 3 GLU E 143 PRO E 144 0 -0.05 SITE 1 AC1 20 PHE A 27 LEU A 77 GLY A 78 CYS A 79 SITE 2 AC1 20 ARG A 84 ARG A 85 LEU A 86 GLY A 87 SITE 3 AC1 20 ILE A 88 GLY A 89 THR A 90 ASN A 117 SITE 4 AC1 20 SER A 119 ASP A 122 PHE A 123 LYS A 126 SITE 5 AC1 20 HOH A 301 HOH A 302 HOH A 304 HOH A 313 SITE 1 AC2 11 VAL A 29 TYR A 31 ARG A 62 ASP A 64 SITE 2 AC2 11 TYR A 73 MET A 75 TYR A 110 HIS A 112 SITE 3 AC2 11 GLN A 114 TYR A 138 TYR A 139 SITE 1 AC3 20 PHE C 27 LEU C 77 GLY C 78 CYS C 79 SITE 2 AC3 20 ARG C 84 ARG C 85 LEU C 86 GLY C 87 SITE 3 AC3 20 ILE C 88 GLY C 89 THR C 90 ASN C 117 SITE 4 AC3 20 SER C 119 ASP C 122 PHE C 123 LYS C 126 SITE 5 AC3 20 HOH C 301 HOH C 303 HOH C 306 HOH C 308 SITE 1 AC4 12 TYR C 31 ARG C 62 ASP C 64 TYR C 73 SITE 2 AC4 12 MET C 75 TYR C 110 HIS C 112 VAL C 113 SITE 3 AC4 12 GLN C 114 TYR C 138 TYR C 139 HOH C 310 SITE 1 AC5 19 PHE E 27 LEU E 77 GLY E 78 CYS E 79 SITE 2 AC5 19 ARG E 84 ARG E 85 LEU E 86 GLY E 87 SITE 3 AC5 19 GLY E 89 THR E 90 ASN E 117 SER E 119 SITE 4 AC5 19 ASP E 122 PHE E 123 TYR E 124 LYS E 126 SITE 5 AC5 19 HOH E 301 HOH E 302 HOH E 305 SITE 1 AC6 13 VAL E 29 TYR E 31 ARG E 62 ASP E 64 SITE 2 AC6 13 TYR E 73 MET E 75 TYR E 110 HIS E 112 SITE 3 AC6 13 VAL E 113 GLN E 114 TYR E 138 TYR E 139 SITE 4 AC6 13 HOH E 311 CRYST1 47.830 102.940 67.640 90.00 106.71 90.00 P 1 21 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.020907 0.000000 0.006276 0.00000 SCALE2 0.000000 0.009714 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015436 0.00000